Growth Metrics

Travere Therapeutics (TVTX) Restructuring Costs (2016 - 2024)

Travere Therapeutics (TVTX) has disclosed Restructuring Costs for 5 consecutive years, with $1.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Restructuring Costs fell 88.02% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, down 89.02%, and an annual FY2024 reading of $2.4 million, down 78.94% over the prior year.
  • Restructuring Costs was $1.4 million for Q4 2024 at Travere Therapeutics, up from $123000.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $11.4 million in Q4 2023 and bottomed at $123000.0 in Q3 2024.